Comparison of single-agent androgen suppression for advanced prostate cancer

Area of Science:

• Oncology
• Endocrinology

Background:

• Gonadotropin-releasing hormone (GnRH) agonists are standard for androgen suppression in advanced prostate cancer.
• Key GnRH agonists include leuprolide, goserelin, triptorelin, and histrelin.

Purpose of the Study:

• To compare the efficacy of different GnRH agonists in maintaining androgen suppression.
• To evaluate the reliability of triptorelin versus leuprolide in achieving castration levels of serum testosterone.

Main Methods:

• Review of existing literature and Food and Drug Administration (FDA) data.
• Analysis of randomized studies comparing single-agent GnRH therapies.

Main Results:

• Limited direct comparative studies exist for GnRH agonists.
• Data suggests triptorelin may be more consistent than leuprolide in maintaining testosterone castration levels.

Conclusions:

• Triptorelin shows potential for improved reliability in testosterone suppression compared to leuprolide.
• The clinical significance of this difference requires further investigation.